Profusa, Inc. reported Q2 2026 financial results and provided an update on its option agreement to acquire G3 Vision Labs. The company executed a $10.7 million Series A Convertible Exchange Agreement, converting $4.57 million into preferred stock, and borrowed $650,000 for working capital. Profusa completed a 4-for-1 reverse stock split effective August 18, 2026, to meet Nasdaq listing requirements. For the quarter ended June 30, 2026, cash on hand was $719,000 against total liabilities of $28.2 million, with a net loss of $8.8 million. The company expects G3's audited financials by mid-September and anticipates stockholders' equity to reach $28.4 million by July 31, 2026. Profusa is a digital health company developing tissue-integrated biosensors for continuous medical data transmission.
